News Sentiment

RPRX sentiment intelligence

Royalty Pharma Plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 75 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 58.18 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 66

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+3.1% over one week, +9.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 3.1% Price confirming higher
Trend fit Trend active 9.9% over four weeks
Fair value 75.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 52
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 66
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 10
simplywall.st 7
MarketBeat 6
TradingView 5
GlobeNewswire 2
Zacks 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 19
Deals and strategy 5
Balance sheet 4
Capital return 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 75
Quiver Quantitative Direct company coverage

Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share

Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation

Tone
Positive 65/100
Event
Earnings
Published
17 Jul 2026 20:21
Source
Quiver Quantitative
Stock Titan Direct company coverage

Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders

Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest buyer of biopharmaceuti

Tone
Positive 71/100
Event
Capital return
Published
17 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Royalty Pharma Plc Class A Stocks

This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:41
Source
TradingView
Stock Titan Direct company coverage

[Form 4] Royalty Pharma plc Insider Trading Activity

Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted o

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades

Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additi

Tone
Negative 28/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M

Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

[144] Royalty Pharma plc SEC Filing

This article reports a Form 144 SEC filing by Royalty Pharma plc (RPRX), indicating a proposed sale of 100,000 Class A Ordinary Shares with an aggregate market value of $5,709,000. These shares were acquired from the issuer in a private transaction on February 14, 2025. The filin

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) director gets equity grant in lieu of cash

Royalty Pharma (RPRX) director Bonnie L. Bassler received an equity grant of 689 Class A Ordinary Shares as compensation, valued at $37,500, in lieu of a quarterly cash retainer. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan, with each

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 05:10
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD

The article mentions the enterprise value to revenue forward for Royalty Pharma Plc Class A, traded on the Stuttgart Stock Exchange under the symbol RPD. It is a financial data point for the company in the Pharmaceuticals: Major industry within Health Technology. The content prov

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Royalty Pharma Plc Class A – SWB:RPD

This article provides access to the "Price to earnings forward" financial metric for Royalty Pharma Plc Class A (SWB:RPD) on TradingView. It indicates that the market for this stock was closed with no trades at the time of access. The primary content focuses on directing users to

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 06:39
Source
TradingView
Stock Titan Direct company coverage

Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan

An entity linked to Christopher Hite, EVP and Chairman, Partnering at Royalty Pharma plc, sold 150,000 Class A Ordinary Shares in open-market transactions on June 23, 2026. These sales, executed at weighted average prices around $54, were pre-planned under a Rule 10b5-1 trading p

Tone
Negative 41/100
Event
Market update
Published
26 Jun 2026 00:41
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Royalty Pharma Plc For: 25 June By Investing.com

This article provides details of a Form 4 filing for Royalty Pharma Plc on June 25, 2026. Form 4 filings typically report changes in beneficial ownership of securities by company insiders. The article also includes current market data for various indices, commodities, and currenc

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:20
Source
Investing.com South Africa